Brief: Biomed Lublin Signs Deal With BMODESTO For Cooperation On ONKO BCG 50 And ONKO BCG 100

Synthaverse SA

20/07/2022 08:29

July 20 (Reuters) - Biomed Lublin Wytwornia Surowic i
Szczepionek SA  BML.WA :
    * SIGNS DEAL WITH BMODESTO
    * TOTAL MINIMUM VALUE OF ORDERS IN FIRST 5 YEARS OF DEAL IS
ESTIMATED AT EUR 10.3 MILLION
    * DEAL IS FOR REGISTRATION, DELIVERY AND DISTRIBUTION OF
COMPANY'S
MEDICAL PRODUCT UNDER TRADE NAME OF ONKO BCG 50 AND ONKO BCG 100
    * UNDER DEAL COMPANY GIVES BMODESTO RIGHT TO SELL AND
DISTRIBUTE
SAID PRODUCT IN NETHERLANDS AFTER ACQUIRING REGISTRATION THERE
    * PARTIES AGREES THAT TERRITORY OF SAID AGREEMENT MAY BE
EXPANDED
BY OTHER EU MARKETS UNDER CONDITIONS AGREED SEPARATELY BY
PARTIES
    * DEAL IS BINDING FOR 10 YEARS COMMENCING ON A DATE OF
OBTAINING
NETHERLANDS' REGISTRATION OF SAID PRODUCT
    * DEAL THEREFORE WILL BE AUTOMATICALLY EXTENDED FOR ANOTHER
5 YEAR
EXTRA PERIODS
    * PARTIES AGREES THAT OBTAINING SAID REGISTRATION AND BY
BMODESTO
AND ADJUSTMENT OF PRODUCTION CAPABILITIES BY BIOMED WILL TAKE
PLACE UNTIL END-2024
    * COMMODIFICATION OF SAID PRODUCT IN NETHERLANDS IS TO TAKE
PLACE
IN 2025, WITH PRECISE DATE TO BE SET BY PARTIES

Source text for Eikon:  ID:nEM5sDN5Ma 
Further company coverage:  BML.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))